



## Clinical trial results:

**A phase II, open-label, non-controlled, intra-patient dose-escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapsed or treatment-naive severe aplastic anemia or recurrent aplastic anemia.**

**Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results.**

**Please use <https://www.novctrd.com> for complete trial results.**

### Summary

EudraCT number	2015-003166-91
Trial protocol	GB PT NL
Global end of trial date	

### Results information

Result version number	v1
This version publication date	11 April 2025
First version publication date	11 April 2025

### Trial information

#### Trial identification

Sponsor protocol code	CETB115E2201
-----------------------	--------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03025698
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Novartis Pharma, AG
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma, AG, 41 613241111, <a href="mailto:novartis.email@novartis.com">novartis.email@novartis.com</a>
Scientific contact	Clinical Disclosure Office, Novartis Pharma, AG, 41 613241111, <a href="mailto:novartis.email@novartis.com">novartis.email@novartis.com</a>

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric	
---------------------------------------	--

investigation plan (PIP)	
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Notes:	

## Results analysis stage

Analysis stage	Interim
Date of interim/final analysis	22 April 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	22 April 2022
Global end of trial reached?	No

Notes:

## General information about the trial

Main objective of the trial:

To characterize the PK of eltrombopag at the highest dose after oral administration in pediatric patients with SAA.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	30 September 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 4
Country: Number of subjects enrolled	Hong Kong: 3
Country: Number of subjects enrolled	Portugal: 1
Country: Number of subjects enrolled	Russian Federation: 10
Country: Number of subjects enrolled	Thailand: 9
Country: Number of subjects enrolled	United States: 24
Worldwide total number of subjects	51
EEA total number of subjects	1

Notes:

### Subjects enrolled per age group

In utero	0
----------	---

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	30
Adolescents (12-17 years)	21
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Due to low participant numbers in Cohort A regimens 1 and 2, this report will focus on total participants in Cohort A and Cohort B.

### Pre-assignment

Screening details:

Study was conducted in 19 sites in 6 countries.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Total Cohort A (Regimens 1 & 2)

Arm description:

Regimen 1: Participants received hATG (ATGAM®), CsA and eltrombopag beginning on Day 1. Regimen 2: Participants received CsA and eltrombopag beginning on Day 1.

Arm type	Experimental
Investigational medicinal product name	Eltrombopag
Investigational medicinal product code	ETB115
Other name	
Pharmaceutical forms	Tablet, Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Eltrombopag tablets were supplied at dose strengths of 12.5 mg, 25 mg, 50 mg, and 75 mg or as a 25 mg powder for oral solution.

<b>Arm title</b>	Cohort B
------------------	----------

Arm description:

Participants who previously had untreated SAA received hATG, CsA and eltrombopag beginning on Day 1.

Arm type	Experimental
Investigational medicinal product name	Eltrombopag
Investigational medicinal product code	ETB115
Other name	
Pharmaceutical forms	Tablet, Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

Eltrombopag tablets were supplied at dose strengths of 12.5 mg, 25 mg, 50 mg, and 75 mg or as a 25 mg powder for oral solution.

<b>Number of subjects in period 1</b>	<b>Total Cohort A (Regimens 1 &amp; 2)</b>	<b>Cohort B</b>
Started	14	37
Subjs who entered 26-wk treatment phase	14	37
Completed 26-week (Wk) treatment	11	25
Entered 52-wk post-trtmnt f/u phase	13	26
Did not enter 52-wk post-trtmnt f/u ph	1 <sup>[1]</sup>	11 <sup>[2]</sup>
Completed	9	19
Not completed	5	18
Adverse event, serious fatal	1	-
Physician decision	1	2
Patient/Guardian Decision	2	4
Progressive Disease	-	1
Did not enter post-treatment f/u 1 (Wk 78)	1	11

---

**Notes:**

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Added for reader clarification

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Added for reader clarification

## Baseline characteristics

### Reporting groups

Reporting group title	Total Cohort A (Regimens 1 & 2)
-----------------------	---------------------------------

Reporting group description:

Regimen 1: Participants received hATG (ATGAM®), CsA and eltrombopag beginning on Day 1. Regimen 2: Participants received CsA and eltrombopag beginning on Day 1.

Reporting group title	Cohort B
-----------------------	----------

Reporting group description:

Participants who previously had untreated SAA received hATG, CsA and eltrombopag beginning on Day 1.

Reporting group values	Total Cohort A (Regimens 1 & 2)	Cohort B	Total
Number of subjects	14	37	51
Age categorical			
Units: Subjects			
Children (2-11 years)	8	22	30
Adolescents (12-17 years)	6	15	21
Age Continuous			
Units: Years			
median	11.0	10.0	
full range (min-max)	4.0 to 17.0	2.0 to 17.0	-
Sex: Female, Male			
Units: Participants			
Female	6	17	23
Male	8	20	28
Race/Ethnicity, Customized			
Units: Subjects			
Caucasian	6	24	30
Black	3	4	7
Asian	4	9	13
Unknown	1	0	1

## End points

### End points reporting groups

Reporting group title	Total Cohort A (Regimens 1 & 2)
Reporting group description: Regimen 1: Participants received hATG (ATGAM®), CsA and eltrombopag beginning on Day 1. Regimen 2: Participants received CsA and eltrombopag beginning on Day 1.	
Reporting group title	Cohort B
Reporting group description: Participants who previously had untreated SAA received hATG, CsA and eltrombopag beginning on Day 1.	
Subject analysis set title	Total Cohort A (Regimens 1 & 2): 1 to < 6 years
Subject analysis set type	Sub-group analysis
Subject analysis set description: Regimen 1: hATG (ATGAM®), CsA and eltrombopag begin on Day 1. Regimen 2: CsA and eltrombopag begin on Day 1.	
Subject analysis set title	Cohort B (1 to < 6 years)
Subject analysis set type	Sub-group analysis
Subject analysis set description: Previously untreated SAA, hATG (ATGAM®), CsA and eltrombopag begin on Day 1 and all patients will be treated with the same regimen	
Subject analysis set title	Total Cohort A (Regimens 1 & 2)
Subject analysis set type	Full analysis
Subject analysis set description: Regimen 1: hATG, CsA and eltrombopag begin on Day 1. Regimen 2: CsA and eltrombopag begin on Day 1.	
Subject analysis set title	Total Participants
Subject analysis set type	Per protocol
Subject analysis set description: Response to all participants in the study exposed to eltrombopag per age group.	
Subject analysis set title	Total Cohort A (Regimens 1 & 2): 1 to < 6 years
Subject analysis set type	Full analysis
Subject analysis set description: Regimen 1: hATG (ATGAM®), CsA and eltrombopag begin on Day 1. Regimen 2: CsA and eltrombopag begin on Day 1.	
Subject analysis set title	Cohort B (1 to < 6 years)
Subject analysis set type	Full analysis
Subject analysis set description: Previously untreated SAA, hATG (ATGAM®), CsA and eltrombopag begin on Day 1 and all patients will be treated with the same regimen	
<b>Primary: Eltrombopag PK parameters: AUCtau, AUClast</b>	
End point title	Eltrombopag PK parameters: AUCtau, AUClast <sup>[1]</sup>
End point description: AUC tau: Area under the curve calculated to the end of the dosing interval ( tau) (mass*time/volume) AUC last: Area under the curve calculated to the last quantifiable concentration point (Tlast) (mass*time/volume)	
End point type	Primary
End point timeframe: 11 weeks after dose initiation or later when patients are taking the highest dose	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistics planned

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B	Total Cohort A (Regimens 1 & 2): 1 to < 6 years	Cohort B (1 to < 6 years)
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	7	15	1	8
Units: hr*ng/mL				
geometric mean (geometric coefficient of variation)				
AUCtau (n = 1, 5, 6, 10)	306000 (± 63.8)	275000 (± 52.6)	272000 (± 999)	502000 (± 65.6)
AUClast	253000 (± 85.8)	259000 (± 75.1)	272000 (± 999)	477000 (± 52.5)

## Statistical analyses

No statistical analyses for this end point

### Primary: Eltrombopag PK parameter: Cmax

End point title	Eltrombopag PK parameter: Cmax <sup>[2]</sup>
End point description:	Cmax is the observed maximum plasma concentration following administration (mass/volume)
End point type	Primary
End point timeframe:	11 weeks after dose initiation or later when patients are taking the highest dose

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistics planned

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B	Total Cohort A (Regimens 1 & 2): 1 to < 6 years	Cohort B (1 to < 6 years)
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	7	15	1	8
Units: ng/mL				
geometric mean (geometric coefficient of variation)	14500 (± 58.2)	15600 (± 47.2)	16100 (± 999)	27100 (± 40.6)

## Statistical analyses

No statistical analyses for this end point

### Primary: Eltrombopag PK parameter: Ctrough at the highest dose level



End point title	Eltrombopag PK parameter: Ctrough at the highest dose level <sup>[3]</sup>
End point description:	Ctrough is the pre-dose plasma concentration (mass/volume).
End point type	Primary
End point timeframe:	11 weeks after dose initiation or later when patients are taking the highest dose
Notes:	[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistics planned

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B	Total Cohort A (Regimens 1 & 2): 1 to < 6 years	Cohort B (1 to < 6 years)
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	7	15	1	8
Units: ng/mL				
geometric mean (geometric coefficient of variation)	9920 (± 56.2)	9670 (± 64.5)	5470 (± 999)	13400 (± 113)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of participants with an overall response and percentage of participants with a platelet response

End point title	Percentage of participants with an overall response and percentage of participants with a platelet response <sup>[4]</sup>
End point description:	Overall response rate (ORR) is defined as the percentage of participants who have achieved a complete response (CR) or partial response (PR) by the Investigator. CR criteria: Platelet (PLT) and red blood cell (RBC) transfusion independence, Normal age-adjusted Hgb, PLT >100 × 10 <sup>9</sup> /L and absolute neutrophil count (ANC) >1.5 × 10 <sup>9</sup> /L. PR: PLT and RBC Transfusion independence and at least 2 of the following criteria: Reticulocytes >30 × 10 <sup>9</sup> /L, PLT >30 × 10 <sup>9</sup> /L, ANC >1.5 × 10 <sup>9</sup> /L. PLT transfusion independence is defined as a period for at least 28 days without PLT transfusion. Platelet response rate (PRR): Platelet response is comprised of CR + PR based on the following criteria: CR: PLT >100 × 10 <sup>9</sup> /L; PR: PLT >30 × 10 <sup>9</sup> /L
End point type	Secondary
End point timeframe:	Week 12, Week 26, Week 52, Week 78
Notes:	[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No statistics planned

End point values	Cohort B	Total Cohort A (Regimens 1 & 2)		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	37	14		
Units: Percentage of participants				
number (confidence interval 95%)				

ORR: Week 12	13.5 (4.5 to 28.8)	35.7 (12.8 to 64.9)		
ORR: Week 26	45.9 (29.5 to 63.1)	71.4 (41.9 to 91.6)		
ORR: Week 52	43.2 (27.1 to 60.5)	50.0 (23.0 to 77.0)		
ORR: Week 78	40.5 (24.8 to 57.9)	57.1 (28.9 to 82.3)		
PRR: Week 12	67.6 (50.2 to 82.0)	71.4 (41.9 to 91.6)		
PRR: Week 26	70.3 (53.0 to 84.1)	71.4 (41.9 to 91.6)		
PRR: Week 52	48.6 (31.9 to 65.6)	57.1 (28.9 to 82.3)		
PRR: Week 78	45.9 (29.5 to 63.1)	57.1 (28.9 to 82.3)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Hematologic counts (platelets (blood), neutrophils (blood))

End point title	Hematologic counts (platelets (blood), neutrophils (blood))
End point description: Individual Platelets (PLT) and neutrophil counts were summarized for all participants.	
End point type	Secondary
End point timeframe: Week 12, Week 26, Week 52, Week 78	

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	37		
Units: Number of counts x 10 <sup>9</sup> /L				
median (full range (min-max))				
Week 12: Platelets (blood) (n = 14, 35)	41.000 (5.00 to 260.00)	50.000 (3.00 to 338.00)		
Week 26: Platelets (blood) (n = 14, 31)	77.000 (3.00 to 222.00)	106.000 (3.00 to 230.00)		
Week 52: Platelets (blood) (n = 11, 19)	159.000 (7.00 to 240.00)	163.000 (28.00 to 318.00)		
Week 78: Platelets (blood) (n = 9, 18)	134.000 (6.00 to 308.00)	152.500 (28.00 to 278.00)		
Week 12: Neutrophils (blood) (n = 14, 35)	1.795 (0.72 to 11.72)	1.100 (0.00 to 8.10)		
Week 26: Neutrophils (blood) (n = 14, 31)	1.7716 (0.52 to 4.60)	1.640 (0.40 to 4.47)		
Week 52: Neutrophils (blood) n = 11, 19)	1.987 (0.17 to 4.29)	2.600 (0.83 to 5.75)		

Week 78: Neutrophils (blood) (n = 9, 18)	2.627 (0.56 to 4.91)	2.292 (0.69 to 5.41)		
--	----------------------	----------------------	--	--

### Statistical analyses

No statistical analyses for this end point

### Secondary: Hematologic counts (hemoglobin (blood))

End point title	Hematologic counts (hemoglobin (blood))
End point description: Individual hemoglobin (Hgb) counts were summarized for all participants.	
End point type	Secondary
End point timeframe: Week 12, Week 26, Week 52, Week 78	

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	37		
Units: g/L				
median (full range (min-max))				
Week 12 (n = 14, 35)	87.5 (64 to 131)	88.0 (57 to 130)		
Week 26 (n = 14, 31)	100.0 (59 to 128)	95.0 (44 to 125)		
Week 52 (n = 11, 19)	105.0 (52 to 138)	110.0 (92 to 133)		
Week 78 (n = 9, 18)	112.0 (67 to 138)	117.0 (97 to 148)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number and frequency of Red Blood Cell (RBC) transfusion

End point title	Number and frequency of Red Blood Cell (RBC) transfusion
End point description: Number of transfusions during the treatment period refers to total number of RBC transfusions participants have received while on treatment. Frequency of transfusions during the treatment period refers to number of RBC transfusions during the treatment period divided by number of months of treatment duration.	
End point type	Secondary
End point timeframe: From date of first dose to approx. 3 years	

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	11	33		
Units: RBC transfusions				
median (full range (min-max))				
Number of RBC transfusions	4.0 (1 to 34)	7.0 (1 to 26)		
Frequency of RBC transfusions	1.2 (0 to 4)	0.9 (0 to 5)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number and frequency of Platelet (PLT) transfusion

End point title	Number and frequency of Platelet (PLT) transfusion
End point description:	
Number of transfusions during the treatment period refers to total number of PLT transfusions participants have received while on treatment.	
Frequency of transfusions during the treatment period refers to number of PLT transfusions during the treatment period divided by number of months of treatment duration.	
End point type	Secondary
End point timeframe:	
From date of first dose to approx. 3 years	

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	34		
Units: Platelet transfusions				
median (full range (min-max))				
Number of platelet transfusions	14.0 (3 to 53)	13.0 (2 to 65)		
Frequency of platelet transfusions	2.4 (0 to 14)	2.0 (0 to 13)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Total duration of Red Blood Cell (RBC) transfusion independence during the treatment period

End point title	Total duration of Red Blood Cell (RBC) transfusion
-----------------	--

## End point description:

RBC transfusion independence is defined as a period of time of at least 56 days without RBC transfusion. Duration of RBC transfusion independence is defined as a period of time of at least 56 days without RBC transfusion. First transfusion duration was calculated as the date of the day before the first transfusion after baseline minus the date of first exposure eltrombopag + 1.

End point type	Secondary
----------------	-----------

## End point timeframe:

From date of first dose to approx. 1074 days

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	25		
Units: days				
median (full range (min-max))				
Duration of RBC transfusion independence	430.0 (185 to 860)	267.0 (58 to 1074)		

## Statistical analyses

No statistical analyses for this end point

**Secondary: Total duration of Platelet (PLT) transfusion independence during the treatment period**

End point title	Total duration of Platelet (PLT) transfusion independence during the treatment period
-----------------	---

## End point description:

Duration of RBC transfusion independence defined as the period of time between a participant's last RBC and platelets transfusion and withdrawal from the trial or trial completion.

End point type	Secondary
----------------	-----------

## End point timeframe:

From date of first dose to approx. 1100 days

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	12	28		
Units: days				
median (full range (min-max))				
Duration of PLT transfusion independence	268.0 (36 to 860)	268.0 (34 to 1100)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maximum duration of platelet (PLT) transfusion independence

End point title	Maximum duration of platelet (PLT) transfusion independence
-----------------	---

End point description:

Maximum duration of PLT transfusion independence that is defined as a period of time of at least 28 days without platelet transfusion. First transfusion duration was calculated as the date of first transfusion after baseline minus the date of first exposure eltrombopag + 1.

End point type	Secondary
----------------	-----------

End point timeframe:

From date of first dose to approx. 3 years

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	12	28		
Units: days				
median (full range (min-max))	268.0 (36 to 860)	249.5 (34 to 1067)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maximum duration of Red Blood Cell (RBC) transfusion independence

End point title	Maximum duration of Red Blood Cell (RBC) transfusion independence
-----------------	---

End point description:

RBC transfusion independence is defined as a period of time of at least 56 days without RBC transfusion. Maximum duration of RBC transfusion independence is defined as a period of time of at least 56 days without RBC transfusion. First transfusion duration was calculated as the date of first transfusion after baseline minus the date of first exposure eltrombopag + 1.

End point type	Secondary
----------------	-----------

End point timeframe:

From date of first dose to approx. 3 years

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	25		
Units: days				
median (full range (min-max))				
RBC	321.0 (185 to 860)	259.0 (58 to 1074)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Bone marrow cellularity

End point title	Overall Bone marrow cellularity
End point description: Percentage of cells in bone marrow biopsy - a comprehensive diagnostic evaluation to distinguish between the various bone marrow disorders.	
End point type	Secondary
End point timeframe: Screening, Week 26, Week 52, Week 78 and then annually up to 3 years	

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	37		
Units: Percentage cellularity cells				
median (full range (min-max))				
Overall cellularity (OC): Screening (n = 14, 26)	15.0 (5.0 to 50.0)	4.0 (2.0 to 40.0)		
OC: Week 26 (n = 11, 30)	30.0 (10.0 to 50.0)	22.5 (2.0 to 55.0)		
OC: Week 52 (n = 8, 16)	45.0 (5.0 to 65.0)	35.0 (3.0 to 55.0)		
OC: Week 78 (n = 7, 15)	35.0 (5.0 to 50.0)	35.0 (3.0 to 70.0)		
Hematologic cellularity (HC): Screening (n=14, 26)	7.5 (1.0 to 45.0)	1.5 (1.0 to 25.0)		
HC: Week 26 (n = 11, 30)	25.0 (5.0 to 45.0)	17.5 (1.0 to 50.0)		
HC: Week 52 (n = 8, 16)	40.0 (3.0 to 50.0)	27.5 (2.0 to 50.0)		
HC: Week 78 (n = 7, 15)	25.0 (3.0 to 40.0)	30.0 (2.0 to 50.0)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Bone marrow morphology

End point title	Bone marrow morphology
-----------------	------------------------

End point description:

Percentage of morphology (erythropoiesis, granulopoiesis, megakaryopoiesis, CD34+ (blast cells) cells in bone marrow aspirate - a comprehensive diagnostic evaluation to distinguish between the various bone marrow disorders.

End point type	Secondary
----------------	-----------

End point timeframe:

Screening, Week, 26, Week 52, Week 78

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	37		
Units: Percentage morphology cells				
median (full range (min-max))				
Erythroid cells: Screening (n = 14, 26)	13.5 (0.0 to 39.0)	5.0 (0.0 to 38.0)		
Erythroid cells: Week 26 (n = 12, 30 )	10.0 (1.0 to 25.0)	18.0 (0.0 to 55.0)		
Erythroid cells: Week 52 (n = 9, 16)	13.0 (2.0 to 37.0)	14.5 (1.0 to 28.0)		
Erythroid cells: Week 78 (n = 7, 14)	15.0 (5.0 to 20.0)	20.5 (4.0 to 26.0)		
Neutrophil: Screening (n = 14, 26)	33.0 (1.0 to 48.0)	8.0 (0.0 to 45.0)		
Neutrophil cells: Week 26 (n = 12, 30)	51.5 (29.0 to 66.0)	50.0 (17.0 to 78.0)		
Neutrophil: Week 52 (n = 9, 16)	57.0 (32.0 to 67.0)	52.5 (20.0 to 76.0)		
Neutrophil: Week 78 (n = 7, 14)	43.0 (4.0 to 54.0)	52.0 (34.0 to 67.0)		
Blast cells: Screening (n = 14, 26)	0.0 (0.0 to 5.0)	0.0 (0.0 to 3.0)		
Blast cells: Week 26 (n = 12, 30)	0.0 (0.0 to 2.0)	0.0 (0.0 to 1.0)		
Blast cells: Week 52 (n = 9, 16)	0.0 (0.0 to 2.0)	0.0 (0.0 to 1.0)		
Blast cells: Week 78 (n = 7, 14)	0.0 (0.0 to 1.0)	1.0 (0.0 to 2.0)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Bone marrow cytogenetics

End point title	Bone marrow cytogenetics
-----------------	--------------------------

End point description:

Number of bone marrow cytogenetics (chromosomal structure) by karyotyping and Fluorescence in situ hybridization (FISH). This is a comprehensive diagnostic evaluation to distinguish between the various bone marrow disorders.



End point type	Secondary
End point timeframe:	
at Week 26	

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	37		
Units: Participants				
Normal	11	28		
Absent	0	0		
Not Available	3	9		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Acceptability and palatability for both tablets and powder formulation for oral solution (PfOS)

End point title	Acceptability and palatability for both tablets and powder formulation for oral solution (PfOS)
End point description:	
Standardized (total) summary score, ranged from 0-100 was derived from all items from the questionnaire based on a scoring matrix. The questionnaire was completed by parents and caregivers of patients under 12 years of age (ObsRO) and a questionnaire completed by patients 12 years and older (PRO).	
End point type	Secondary
End point timeframe:	
From Day 1 to up to Week 78	

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	37		
Units: scores on a scale (of acceptability)				
median (full range (min-max))				
Acceptability (including palatability) - Tablet	75.0 (58.0 to 96.0)	71.0 (46.0 to 96.0)		
Acceptability (including palatability) - PfOS	999 (999 to 999)	71.0 (46.0 to 96.0)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Clonal evolution to Paroxysmal Nocturnal Hemoglobinuria (PNH)

End point title	Clonal evolution to Paroxysmal Nocturnal Hemoglobinuria (PNH)
-----------------	---

End point description:

Percentage of participants with clonal evolution to PNH.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week (W) 26 Day (D) 1, W52D1, W78D1

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	37		
Units: Percentage of participants				
number (not applicable)				
Baseline: Positive clonal evolution:	21.4	29.7		
Baseline: Negative clonal evolution:	78.6	64.9		
W26D1: Positive clonal evolution:	21.4	8.1		
W26D1: Negative clonal evolution:	64.3	64.9		
W52D1: Positive clonal evolution:	7.1	2.7		
W52D1: Negative clonal evolution:	28.6	29.7		
W78D1: Positive clonal evolution:	7.1	0		
W78D1: Negative clonal evolution:	35.7	21.6		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Exposure (AUCtau) - response relationship of eltrombopag and overall response rate by age groups - Total participants

End point title	Exposure (AUCtau) - response relationship of eltrombopag and overall response rate by age groups - Total participants
-----------------	---

End point description:

Pharmacokinetic parameter (AUCtau) of eltrombopag at the highest dose in relationship to overall response rate.

AUC tau: Area under the curve calculated to the end of the dosing interval ( tau)  
(mass\*time/volume)

End point type	Secondary
----------------	-----------

End point timeframe:

From Day 1 to up to Week 78

End point values	Total Participants			
Subject group type	Subject analysis set			
Number of subjects analysed	10			
Units: hr*ng/mL				
geometric mean (geometric coefficient of variation)				
Complete response (CR): 1 to < 6 yrs (n = 1)	2260000 (± 999)			
Partial Response (PR): 1 to < 6 yrs (n = 1)	671000 (± 999)			
No response (NR): 1 to < 6 yrs (n = 5)	1160000 (± 30.9)			
Complete response (CR): 6 to < 18 yrs (n = 10)	571000 (± 65.6)			
Partial Response (PR): 6 to < 18 yrs (n = 4)	1020000 (± 64.5)			
No Response (NR): 6 to < 18 yrs (n = 1)	390000 (± 999)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Exposure (Cmax, Ctrough) - response relationship of eltrombopag and overall response rate by age groups - Total participants

End point title	Exposure (Cmax, Ctrough) - response relationship of eltrombopag and overall response rate by age groups - Total participants
End point description:	
Pharmacokinetic parameters (Cmax and Ctrough) of eltrombopag at the highest dose in relationship to overall response rate. Cmax is the observed maximum plasma concentration following administration (mass/volume). Ctrough is the pre-dose plasma concentration (mass/volume).	
End point type	Secondary
End point timeframe:	
From Day 1 to up to Week 78	

End point values	Total Participants			
Subject group type	Subject analysis set			
Number of subjects analysed	12			
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Cmax - CR: 1 to < 6 yrs (n = 1)	112000 (± 999)			
Cmax - PR: 1 to < 6 yrs (n = 3)	60500 (± 26.6)			
Cmax- NR: 1 to < 6 yrs (n = 5)	759000 (± 38.6)			
Cmax - CR: 6 to < 18 yrs (n = 12)	32300 (± 65.4)			
Cmax - PR: 6 to < 18 yrs (n = 6)	41700 (± 96.4)			

Cmax - NR: 6 to < 18 yrs (n = 4)	36400 (± 61.7)			
Ctrough - CR: 1 to < 6 yrs (n = 1)	84700 (± 999)			
Ctrough - PR: 1 to < 6 yrs (n = 3)	23800 (± 194)			
Ctrough - NR: 1 to < 6 yrs (n = 5)	32000 (± 48.9)			
Ctrough - CR: 6 to < 18 yrs (n = 12)	21600 (± 76.5)			
Ctrough - PR: 6 to < 18 yrs (n = 6)	27800 (± 90.1)			
Ctrough - NR: 6 to < 18 yrs (n = 4)	19200 (± 60.3)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Exposure (AUCtau) - response relationship of eltrombopag and platelet response rate by age groups - Total participants

End point title	Exposure (AUCtau) - response relationship of eltrombopag and platelet response rate by age groups - Total participants
End point description:	
Pharmacokinetic parameter (AUCtau) of eltrombopag at the highest dose in relationship to platelet response rate.	
AUC tau: Area under the curve calculated to the end of the dosing interval ( tau) (mass*time/volume)	
End point type	Secondary
End point timeframe:	
From Day 1 to up to Week 78	

End point values	Total Participants			
Subject group type	Subject analysis set			
Number of subjects analysed	13			
Units: hr*ng/mL				
geometric mean (geometric coefficient of variation)				
Complete response (CR): 1 to < 6 yrs (n = 2)	1670000 (± 45.2)			
Partial Response (PR): 1 to < 6 yrs (n = 4)	1090000 (± 43.5)			
No response (NR): 1 to < 6 yrs (n = 1)	816000 (± 999)			
Complete response (CR): 6 to < 18 yrs (n = 13)	642000 (± 70.0)			
Partial Response (PR): 6 to < 18 yrs (n = 1)	390000 (± 999)			
No Response (NR): 6 to < 18 yrs (n = 1)	1280000 (± 999)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Exposure (Cmax, Ctrough) - response relationship of eltrombopag and platelet response rate by age groups - Total participants

End point title	Exposure (Cmax, Ctrough) - response relationship of eltrombopag and platelet response rate by age groups - Total participants
-----------------	---

End point description:

Pharmacokinetic parameters (Cmax and Ctrough) of eltrombopag at the highest dose in relationship to platelet response rate.

Cmax is the observed maximum plasma concentration following administration (mass/volume).

Ctrough is the pre-dose plasma concentration (mass/volume).

End point type	Secondary
----------------	-----------

End point timeframe:

or up to Week 26 when the PK highest dose has been achieved

End point values	Total Participants			
Subject group type	Subject analysis set			
Number of subjects analysed	38			
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Cmax - CR: 1 to < 6 yrs (n = 4)	80900 (± 31.7)			
Cmax - PR: 1 to < 6 yrs (n = 4)	74000 (± 42.1)			
Cmax- NR: 1 to < 6 yrs (n = 1)	48400 (± 999)			
Cmax - CR: 6 to < 18 yrs (n = 17)	33800 (± 74.3)			
Cmax - PR: 6 to < 18 yrs (n = 3)	30100 (± 54.8)			
Cmax - NR: 6 to < 18 yrs (n = 2)	65700 (± 1.83)			
Ctrough - CR: 1 to < 6 yrs (n = 4)	50100 (± 48.8)			
Ctrough - PR: 1 to < 6 yrs (n = 4)	24600 (± 132)			
Ctrough - NR: 1 to < 6 yrs (n = 1)	16400 (± 999)			
Ctrough - CR: 6 to < 18 yrs (n = 17)	22600 (± 79.5)			
Ctrough - PR: 6 to < 18 yrs (n = 3)	15500 (± 45.4)			
Ctrough - NR: 6 to < 18 yrs (n = 2)	40700 (± 14.3)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Alternate overall response rate (aORR)

End point title	Alternate overall response rate (aORR)
-----------------	--

End point description:

Alternate overall responses were derived using hematological parameters (i.e., hemoglobin, platelet, reticulocyte, and ANC). aORR is defined as the percentage of participants who achieved an alternate complete response (aCR) or an alternate partial response (aPR)

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12, Week 26, Week 52, and Week 78.

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	37		
Units: Percentage of participants				
number (confidence interval 95%)				
Week 12	92.9 (66.1 to 99.8)	64.9 (47.5 to 79.8)		
Week 26	92.9 (66.1 to 99.8)	75.7 (58.8 to 88.2)		
Week 52	35.7 (12.8 to 64.9)	40.5 (24.8 to 57.9)		
Week 78	57.1 (28.9 to 82.3)	48.6 (31.9 to 65.6)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Pharmacokinetics (PK) of eltrombopag at the starting dose (AUCtau)

End point title	Pharmacokinetics (PK) of eltrombopag at the starting dose (AUCtau)
-----------------	--

End point description:

PK parameter, AUCtau.

AUC tau: Area under the curve calculated to the end of the dosing interval (tau) (mass\*time/volume)

End point type	Secondary
----------------	-----------

End point timeframe:

Week 3 Day 1

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	12		
Units: hr*ng/mL				
geometric mean (geometric coefficient of variation)	367000 (± 37.0)	441000 (± 55.2)		

### Statistical analyses

No statistical analyses for this end point

**Secondary: PK of eltrombopag at the starting dose (Cmax)**

End point title	PK of eltrombopag at the starting dose (Cmax)
End point description: PK parameter, Cmax Cmax is the observed maximum plasma concentration following administration (mass/volume)	
End point type	Secondary
End point timeframe: Week 3 Day 1	

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	16		
Units: ng/mL				
geometric mean (geometric coefficient of variation)	20100 ( $\pm$ 38.5)	24000 ( $\pm$ 51.0)		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: PK of eltrombopag at the starting dose (Ctrough)**

End point title	PK of eltrombopag at the starting dose (Ctrough)
End point description: PK parameter, Ctrough Ctrough is the pre-dose plasma concentration (mass/volume).	
End point type	Secondary
End point timeframe: Week 3 Day 1	

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	16		
Units: ng/mL				
geometric mean (geometric coefficient of variation)	9430 ( $\pm$ 67.0)	13200 ( $\pm$ 52.2)		

**Statistical analyses**

No statistical analyses for this end point

### Post-hoc: All Collected Deaths

End point title	All Collected Deaths
-----------------	----------------------

End point description:

Adverse events and on-treatment deaths were collected from the first dose of study treatment up to 30 days after last dose of study medication, for a maximum duration of XXX days.

Post-treatment survival follow-up deaths were collected 31 days after last dose of study medication until the end of the study, up to XXX days.

End point type	Post-hoc
----------------	----------

End point timeframe:

Pre-treatment deaths: from randomization up to before treatment, Post-treatment survival follow-up deaths: Up to approx. XXX months after the end of treatment for the data cut-off, approx. XXX weeks

End point values	Total Cohort A (Regimens 1 & 2)	Cohort B	Total Cohort A (Regimens 1 & 2): 1 to < 6 years	Cohort B (1 to < 6 years)
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	14	37	10	37
Units: Participants				
Total deaths	1	1	0	0
Pre-treatment deaths	1	1	0	0
On-treatment deaths	0	0	0	0

### Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse Events (AEs) were collected from first dosing (Day 1) until date of the last follow-up for the primary analysis, up to 234 weeks.

Adverse event reporting additional description:

An Adverse Event (AE) is any untoward medical occurrence in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.1
--------------------	------

### Reporting groups

Reporting group title	Cohort A (Regimen 2)
-----------------------	----------------------

Reporting group description:

Regimen 2: CsA and eltrombopag begin on Day 1.

Reporting group title	Cohort A (Regimen 1)
-----------------------	----------------------

Reporting group description:

Regimen 1: hATG (ATGAM®), CsA and eltrombopag begin on Day 1.

Reporting group title	Cohort B
-----------------------	----------

Reporting group description:

Previously untreated SAA, hATG (ATGAM®), CsA and eltrombopag begin on Day 1 and all patients will be treated with the same regimen

Reporting group title	Total Patients
-----------------------	----------------

Reporting group description:

All participant in Total Cohort A & Cohort B.

Reporting group title	Total Cohort A (Regimens 1 & 2)
-----------------------	---------------------------------

Reporting group description:

Regimen 1: hATG (ATGAM®), CsA and eltrombopag begin on Day 1. Regimen 2: CsA and eltrombopag begin on Day 1.

Serious adverse events	Cohort A (Regimen 2)	Cohort A (Regimen 1)	Cohort B
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 4 (50.00%)	4 / 10 (40.00%)	23 / 37 (62.16%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			

Fatigue			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	2 / 37 (5.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 4 (25.00%)	2 / 10 (20.00%)	8 / 37 (21.62%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Serum sickness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	2 / 37 (5.41%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Abnormal uterine bleeding			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Hypoxia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oropharyngeal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillar exudate			

subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device malfunction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Platelet count decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver function test increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Toxicity to various agents			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sunburn			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nervous system disorders			
Headache			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	1 / 4 (25.00%)	1 / 10 (10.00%)	5 / 37 (13.51%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Ileus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gingival pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			

subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Drug-induced liver injury			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Petechiae			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	2 / 37 (5.41%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Azotaemia	subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria	subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations				
Anal abscess	subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis	subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes simplex	subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis	subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
	occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection	subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection	subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
	occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis				

subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacillus bacteraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella sepsis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metapneumovirus infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			

subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 37 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decreased appetite			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			



subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypomagnesaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Magnesium metabolism disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Total Patients	Total Cohort A (Regimens 1 & 2)	
Total subjects affected by serious adverse events			
subjects affected / exposed	29 / 51 (56.86%)	6 / 14 (42.86%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	2 / 51 (3.92%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	11 / 51 (21.57%)	3 / 14 (21.43%)	
occurrences causally related to treatment / all	0 / 16	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Serum sickness			
subjects affected / exposed	2 / 51 (3.92%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Abnormal uterine bleeding			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Hypoxia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oropharyngeal pain			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory disorder			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillar exudate			

subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device malfunction			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Platelet count decreased			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test increased			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Toxicity to various agents			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sunburn			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Nervous system disorders			
Headache			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	7 / 51 (13.73%)	2 / 14 (14.29%)	
occurrences causally related to treatment / all	0 / 14	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Ileus			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gingival pain			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stomatitis			

subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal haemorrhage			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Drug-induced liver injury			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperbilirubinaemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Petechiae			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	3 / 51 (5.88%)	1 / 14 (7.14%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Azotaemia	subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
	occurrences causally related to treatment / all	0 / 1	0 / 0	
	deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria	subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
	occurrences causally related to treatment / all	0 / 1	0 / 0	
	deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations				
Anal abscess	subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
	occurrences causally related to treatment / all	0 / 1	0 / 0	
	deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis	subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
	occurrences causally related to treatment / all	0 / 1	0 / 0	
	deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes simplex	subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
	occurrences causally related to treatment / all	0 / 1	0 / 0	
	deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis	subjects affected / exposed	2 / 51 (3.92%)	1 / 14 (7.14%)	
	occurrences causally related to treatment / all	0 / 2	0 / 1	
	deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection	subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
	occurrences causally related to treatment / all	0 / 1	0 / 0	
	deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection	subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
	occurrences causally related to treatment / all	0 / 2	0 / 2	
	deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchiolitis				

subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacillus bacteraemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Klebsiella sepsis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metapneumovirus infection			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous abscess			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			
subjects affected / exposed	2 / 51 (3.92%)	1 / 14 (7.14%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal bacteraemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus infection			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			

subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillitis			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Varicella			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decreased appetite			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrolyte imbalance			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			



subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypomagnesaemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Magnesium metabolism disorder			
subjects affected / exposed	1 / 51 (1.96%)	0 / 14 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Cohort A (Regimen 2)	Cohort A (Regimen 1)	Cohort B
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 4 (100.00%)	10 / 10 (100.00%)	37 / 37 (100.00%)
Vascular disorders			
Thrombophlebitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Hyperaemia			

subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences (all)	1	0	0
Hypertension			
subjects affected / exposed	1 / 4 (25.00%)	4 / 10 (40.00%)	15 / 37 (40.54%)
occurrences (all)	2	8	19
Hypotension			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	2 / 37 (5.41%)
occurrences (all)	1	0	2
Poor peripheral circulation			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
Catheter site pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	2 / 37 (5.41%)
occurrences (all)	0	0	2
Chills			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	3 / 37 (8.11%)
occurrences (all)	0	1	3
Pyrexia			
subjects affected / exposed	1 / 4 (25.00%)	3 / 10 (30.00%)	10 / 37 (27.03%)
occurrences (all)	3	4	15
Pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	2 / 37 (5.41%)
occurrences (all)	0	1	2
Oedema peripheral			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences (all)	1	0	1
Fatigue			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	5 / 37 (13.51%)
occurrences (all)	0	0	7
Feeling hot			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences (all)	1	0	1
Non-cardiac chest pain			

subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 10 (0.00%) 0	2 / 37 (5.41%) 2
Face oedema subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 10 (0.00%) 0	1 / 37 (2.70%) 1
Immune system disorders Anaphylactic shock subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 10 (0.00%) 0	0 / 37 (0.00%) 0
Haemophagocytic lymphohistiocytosis subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 10 (0.00%) 0	0 / 37 (0.00%) 0
Serum sickness subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	2 / 10 (20.00%) 2	6 / 37 (16.22%) 6
Reproductive system and breast disorders Heavy menstrual bleeding subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	2 / 10 (20.00%) 3	1 / 37 (2.70%) 3
Respiratory, thoracic and mediastinal disorders Laryngospasm subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 2	0 / 37 (0.00%) 0
Acute respiratory distress syndrome subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 1	0 / 37 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	2 / 10 (20.00%) 3	3 / 37 (8.11%) 4
Epistaxis subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	2 / 10 (20.00%) 3	5 / 37 (13.51%) 10
Nasal congestion subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 10 (0.00%) 0	3 / 37 (8.11%) 4

Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 10 (10.00%) 1	3 / 37 (8.11%) 5
Rhinorrhoea subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 4	0 / 10 (0.00%) 0	1 / 37 (2.70%) 1
Tonsillar exudate subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 1	0 / 37 (0.00%) 0
Nasal obstruction subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 2	0 / 10 (0.00%) 0	0 / 37 (0.00%) 0
Psychiatric disorders Psychotic disorder subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 1	0 / 37 (0.00%) 0
Insomnia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 10 (0.00%) 0	3 / 37 (8.11%) 3
Anxiety subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 10 (0.00%) 0	5 / 37 (13.51%) 5
Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	7 / 10 (70.00%) 14	16 / 37 (43.24%) 32
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	6 / 10 (60.00%) 11	13 / 37 (35.14%) 24
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 10 (10.00%) 1	1 / 37 (2.70%) 1
Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	6 / 10 (60.00%) 16	18 / 37 (48.65%) 39
Blood creatinine increased			

subjects affected / exposed	2 / 4 (50.00%)	5 / 10 (50.00%)	12 / 37 (32.43%)
occurrences (all)	3	13	15
Blood folate decreased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences (all)	1	0	0
Blood glucose increased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences (all)	1	0	1
Blood phosphorus increased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences (all)	1	0	0
Blood pressure increased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	5 / 37 (13.51%)
occurrences (all)	1	0	5
Blood urea increased			
subjects affected / exposed	3 / 4 (75.00%)	4 / 10 (40.00%)	5 / 37 (13.51%)
occurrences (all)	8	7	6
Immunosuppressant drug level increased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences (all)	1	0	0
Klebsiella test positive			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences (all)	1	0	0
Liver function test increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	2 / 37 (5.41%)
occurrences (all)	0	0	2
SARS-CoV-2 test negative			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences (all)	5	0	0
Serum ferritin increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	2 / 37 (5.41%)
occurrences (all)	0	0	2
Staphylococcus test positive			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences (all)	1	0	0

Blood magnesium decreased subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 10 (0.00%) 0	2 / 37 (5.41%) 2
Injury, poisoning and procedural complications			
Transfusion reaction subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 10 (0.00%) 0	2 / 37 (5.41%) 2
Refractoriness to platelet transfusion subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 10 (0.00%) 0	2 / 37 (5.41%) 2
Procedural pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 10 (0.00%) 0	2 / 37 (5.41%) 2
Infusion related reaction subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 10 (0.00%) 0	2 / 37 (5.41%) 2
Accidental overdose subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 1	0 / 37 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 10 (10.00%) 1	3 / 37 (8.11%) 4
Cardiac disorders			
Tachycardia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 10 (0.00%) 0	2 / 37 (5.41%) 3
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	2 / 10 (20.00%) 6	8 / 37 (21.62%) 10
Syncope subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 1	0 / 37 (0.00%) 0
Tremor subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 1	1 / 37 (2.70%) 1

Dizziness subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 10 (0.00%) 0	2 / 37 (5.41%) 2
Blood and lymphatic system disorders			
Aplastic anaemia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 10 (0.00%) 0	2 / 37 (5.41%) 2
Lymphadenopathy subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 10 (0.00%) 0	2 / 37 (5.41%) 2
Haemolysis subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 10 (0.00%) 0	0 / 37 (0.00%) 0
Febrile neutropenia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	2 / 10 (20.00%) 2	8 / 37 (21.62%) 14
Ear and labyrinth disorders			
Ear pain subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 10 (0.00%) 0	0 / 37 (0.00%) 0
Eye disorders			
Accommodation disorder subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 1	0 / 37 (0.00%) 0
Choroidal effusion subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 10 (0.00%) 0	0 / 37 (0.00%) 0
Dry eye subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 10 (0.00%) 0	2 / 37 (5.41%) 3
Conjunctival haemorrhage subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 2	0 / 10 (0.00%) 0	0 / 37 (0.00%) 0
Eye pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 2	1 / 37 (2.70%) 1
Gastrointestinal disorders			

Abdominal pain			
subjects affected / exposed	2 / 4 (50.00%)	1 / 10 (10.00%)	13 / 37 (35.14%)
occurrences (all)	3	1	17
Abdominal distension			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	2 / 37 (5.41%)
occurrences (all)	0	0	2
Constipation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	6 / 37 (16.22%)
occurrences (all)	0	0	6
Aphthous ulcer			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences (all)	3	0	1
Chronic gastritis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Abdominal pain upper			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	5 / 37 (13.51%)
occurrences (all)	2	0	5
Periodontal disease			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	1 / 37 (2.70%)
occurrences (all)	0	1	1
Oral pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	1 / 37 (2.70%)
occurrences (all)	0	1	1
Oral blood blister			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	2 / 37 (5.41%)
occurrences (all)	0	0	2
Anal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Enterocolitis			
subjects affected / exposed	0 / 4 (0.00%)	2 / 10 (20.00%)	3 / 37 (8.11%)
occurrences (all)	0	3	5
Gastritis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 37 (0.00%)
occurrences (all)	0	1	0



Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	2 / 37 (5.41%)
occurrences (all)	0	0	2
Diarrhoea			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	9 / 37 (24.32%)
occurrences (all)	4	0	11
Small intestinal obstruction			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Mucous stools			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences (all)	1	0	0
Nausea			
subjects affected / exposed	1 / 4 (25.00%)	2 / 10 (20.00%)	17 / 37 (45.95%)
occurrences (all)	2	2	27
Odynophagia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences (all)	3	0	0
Stomatitis			
subjects affected / exposed	1 / 4 (25.00%)	1 / 10 (10.00%)	6 / 37 (16.22%)
occurrences (all)	3	1	6
Gingival hypertrophy			
subjects affected / exposed	3 / 4 (75.00%)	0 / 10 (0.00%)	4 / 37 (10.81%)
occurrences (all)	3	0	5
Haematochezia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences (all)	3	0	0
Gingival swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	3 / 37 (8.11%)
occurrences (all)	0	0	3
Tongue ulceration			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences (all)	2	0	0
Mouth ulceration			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences (all)	1	0	1

Vomiting subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 6	1 / 10 (10.00%) 1	18 / 37 (48.65%) 31
Gingival pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 10 (0.00%) 0	2 / 37 (5.41%) 2
Gingival bleeding subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 3	0 / 10 (0.00%) 0	5 / 37 (13.51%) 7
Hepatobiliary disorders Hyperbilirubinaemia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 2	2 / 37 (5.41%) 2
Jaundice subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 10 (0.00%) 0	2 / 37 (5.41%) 2
Ocular icterus subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 3	0 / 37 (0.00%) 0
Skin and subcutaneous tissue disorders Erythema subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 2	0 / 10 (0.00%) 0	1 / 37 (2.70%) 1
Petechiae subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 2	0 / 10 (0.00%) 0	3 / 37 (8.11%) 8
Alopecia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 10 (0.00%) 0	0 / 37 (0.00%) 0
Ecchymosis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 3	0 / 37 (0.00%) 0
Hirsutism subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 2	0 / 10 (0.00%) 0	3 / 37 (8.11%) 3
Acne			

subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	1 / 37 (2.70%)
occurrences (all)	0	1	1
Pruritus			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	4 / 37 (10.81%)
occurrences (all)	1	0	4
Rash			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	10 / 37 (27.03%)
occurrences (all)	0	1	11
Rash maculo-papular			
subjects affected / exposed	1 / 4 (25.00%)	1 / 10 (10.00%)	2 / 37 (5.41%)
occurrences (all)	1	1	3
Rash papular			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences (all)	1	0	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 4 (0.00%)	2 / 10 (20.00%)	2 / 37 (5.41%)
occurrences (all)	0	2	3
Urticaria			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	6 / 37 (16.22%)
occurrences (all)	0	3	6
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 4 (25.00%)	1 / 10 (10.00%)	3 / 37 (8.11%)
occurrences (all)	1	1	6
Renal tubular acidosis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences (all)	1	0	0
Azotaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Nephropathy toxic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Paroxysmal nocturnal haemoglobinuria			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 1	0 / 37 (0.00%) 0
Renal failure subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 10 (0.00%) 0	0 / 37 (0.00%) 0
Renal impairment subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 10 (0.00%) 0	0 / 37 (0.00%) 0
Endocrine disorders Adrenal insufficiency subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	2 / 10 (20.00%) 2	1 / 37 (2.70%) 1
Cushingoid subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 1	1 / 37 (2.70%) 1
Musculoskeletal and connective tissue disorders Pain in extremity subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 2	2 / 10 (20.00%) 3	5 / 37 (13.51%) 6
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 1	1 / 37 (2.70%) 2
Arthralgia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 10 (10.00%) 3	4 / 37 (10.81%) 5
Back pain subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 10 (10.00%) 2	2 / 37 (5.41%) 2
Kyphosis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 1	0 / 37 (0.00%) 0
Tendon pain subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 10 (0.00%) 0	0 / 37 (0.00%) 0
Infections and infestations			

Rhinitis			
subjects affected / exposed	0 / 4 (0.00%)	2 / 10 (20.00%)	2 / 37 (5.41%)
occurrences (all)	0	2	3
Respiratory tract infection viral			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Pharyngitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	2 / 37 (5.41%)
occurrences (all)	0	1	2
Bacterial disease carrier			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences (all)	1	0	0
COVID-19			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	2 / 37 (5.41%)
occurrences (all)	0	0	2
Epididymitis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	0 / 37 (0.00%)
occurrences (all)	1	0	0
Escherichia bacteraemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Fungal infection			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences (all)	1	0	1
Gingivitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Soft tissue infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	0 / 37 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 10 (0.00%)	1 / 37 (2.70%)
occurrences (all)	1	0	1
Paronychia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	2 / 37 (5.41%)
occurrences (all)	0	0	2

Molluscum contagiosum subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 10 (0.00%) 0	0 / 37 (0.00%) 0
Vascular device infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 1	0 / 37 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 2	0 / 10 (0.00%) 0	7 / 37 (18.92%) 9
Tonsillitis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 1	4 / 37 (10.81%) 7
Metabolism and nutrition disorders			
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 1	3 / 37 (8.11%) 8
Hypermagnesaemia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 10 (10.00%) 2	0 / 37 (0.00%) 0
Dehydration subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 10 (0.00%) 0	2 / 37 (5.41%) 2
Fluid retention subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 10 (0.00%) 0	2 / 37 (5.41%) 2
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	2 / 10 (20.00%) 6	1 / 37 (2.70%) 1
Decreased appetite subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 10 (0.00%) 0	5 / 37 (13.51%) 5
Hypervolaemia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 10 (0.00%) 0	2 / 37 (5.41%) 2
Hypokalaemia			

subjects affected / exposed	0 / 4 (0.00%)	1 / 10 (10.00%)	4 / 37 (10.81%)
occurrences (all)	0	1	5
Hypomagnesaemia			
subjects affected / exposed	1 / 4 (25.00%)	3 / 10 (30.00%)	15 / 37 (40.54%)
occurrences (all)	2	7	21
Hyponatraemia			
subjects affected / exposed	1 / 4 (25.00%)	1 / 10 (10.00%)	1 / 37 (2.70%)
occurrences (all)	3	1	1
Vitamin D deficiency			
subjects affected / exposed	0 / 4 (0.00%)	0 / 10 (0.00%)	2 / 37 (5.41%)
occurrences (all)	0	0	2
Metabolic acidosis			
subjects affected / exposed	1 / 4 (25.00%)	1 / 10 (10.00%)	0 / 37 (0.00%)
occurrences (all)	2	1	0
Iron overload			
subjects affected / exposed	0 / 4 (0.00%)	2 / 10 (20.00%)	4 / 37 (10.81%)
occurrences (all)	0	2	4

<b>Non-serious adverse events</b>	Total Patients	Total Cohort A (Regimens 1 & 2)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	51 / 51 (100.00%)	14 / 14 (100.00%)	
Vascular disorders			
Thrombophlebitis			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	1	1	
Hyperaemia			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	1	1	
Hypertension			
subjects affected / exposed	20 / 51 (39.22%)	5 / 14 (35.71%)	
occurrences (all)	29	10	
Hypotension			
subjects affected / exposed	3 / 51 (5.88%)	1 / 14 (7.14%)	
occurrences (all)	3	1	
Poor peripheral circulation			

subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 14 (7.14%) 1	
General disorders and administration site conditions			
Catheter site pain			
subjects affected / exposed	2 / 51 (3.92%)	0 / 14 (0.00%)	
occurrences (all)	2	0	
Chills			
subjects affected / exposed	4 / 51 (7.84%)	1 / 14 (7.14%)	
occurrences (all)	4	1	
Pyrexia			
subjects affected / exposed	14 / 51 (27.45%)	4 / 14 (28.57%)	
occurrences (all)	22	7	
Pain			
subjects affected / exposed	3 / 51 (5.88%)	1 / 14 (7.14%)	
occurrences (all)	3	1	
Oedema peripheral			
subjects affected / exposed	2 / 51 (3.92%)	1 / 14 (7.14%)	
occurrences (all)	2	1	
Fatigue			
subjects affected / exposed	5 / 51 (9.80%)	0 / 14 (0.00%)	
occurrences (all)	7	0	
Feeling hot			
subjects affected / exposed	2 / 51 (3.92%)	1 / 14 (7.14%)	
occurrences (all)	2	1	
Non-cardiac chest pain			
subjects affected / exposed	3 / 51 (5.88%)	1 / 14 (7.14%)	
occurrences (all)	3	1	
Face oedema			
subjects affected / exposed	2 / 51 (3.92%)	1 / 14 (7.14%)	
occurrences (all)	2	1	
Immune system disorders			
Anaphylactic shock			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	1	1	
Haemophagocytic lymphohistiocytosis			



subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 14 (7.14%) 1	
Serum sickness subjects affected / exposed occurrences (all)	8 / 51 (15.69%) 8	2 / 14 (14.29%) 2	
Reproductive system and breast disorders Heavy menstrual bleeding subjects affected / exposed occurrences (all)	3 / 51 (5.88%) 6	2 / 14 (14.29%) 3	
Respiratory, thoracic and mediastinal disorders Laryngospasm subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 2	1 / 14 (7.14%) 2	
Acute respiratory distress syndrome subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 14 (7.14%) 1	
Cough subjects affected / exposed occurrences (all)	5 / 51 (9.80%) 7	2 / 14 (14.29%) 3	
Epistaxis subjects affected / exposed occurrences (all)	8 / 51 (15.69%) 14	3 / 14 (21.43%) 4	
Nasal congestion subjects affected / exposed occurrences (all)	4 / 51 (7.84%) 5	1 / 14 (7.14%) 1	
Oropharyngeal pain subjects affected / exposed occurrences (all)	5 / 51 (9.80%) 7	2 / 14 (14.29%) 2	
Rhinorrhoea subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 5	1 / 14 (7.14%) 4	
Tonsillar exudate subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 14 (7.14%) 1	
Nasal obstruction			

subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 2	1 / 14 (7.14%) 2	
Psychiatric disorders			
Psychotic disorder			
subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 14 (7.14%) 1	
Insomnia			
subjects affected / exposed occurrences (all)	3 / 51 (5.88%) 3	0 / 14 (0.00%) 0	
Anxiety			
subjects affected / exposed occurrences (all)	5 / 51 (9.80%) 5	0 / 14 (0.00%) 0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed occurrences (all)	24 / 51 (47.06%) 47	8 / 14 (57.14%) 15	
Aspartate aminotransferase increased			
subjects affected / exposed occurrences (all)	20 / 51 (39.22%) 36	7 / 14 (50.00%) 12	
Blood alkaline phosphatase increased			
subjects affected / exposed occurrences (all)	3 / 51 (5.88%) 3	2 / 14 (14.29%) 2	
Blood bilirubin increased			
subjects affected / exposed occurrences (all)	24 / 51 (47.06%) 55	6 / 14 (42.86%) 16	
Blood creatinine increased			
subjects affected / exposed occurrences (all)	19 / 51 (37.25%) 31	7 / 14 (50.00%) 16	
Blood folate decreased			
subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 14 (7.14%) 1	
Blood glucose increased			
subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	1 / 14 (7.14%) 1	
Blood phosphorus increased			

subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	1	1	
Blood pressure increased			
subjects affected / exposed	6 / 51 (11.76%)	1 / 14 (7.14%)	
occurrences (all)	6	1	
Blood urea increased			
subjects affected / exposed	12 / 51 (23.53%)	7 / 14 (50.00%)	
occurrences (all)	21	15	
Immunosuppressant drug level increased			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	1	1	
Klebsiella test positive			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	1	1	
Liver function test increased			
subjects affected / exposed	2 / 51 (3.92%)	0 / 14 (0.00%)	
occurrences (all)	2	0	
SARS-CoV-2 test negative			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	5	5	
Serum ferritin increased			
subjects affected / exposed	2 / 51 (3.92%)	0 / 14 (0.00%)	
occurrences (all)	2	0	
Staphylococcus test positive			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	1	1	
Blood magnesium decreased			
subjects affected / exposed	2 / 51 (3.92%)	0 / 14 (0.00%)	
occurrences (all)	2	0	
Injury, poisoning and procedural complications			
Transfusion reaction			
subjects affected / exposed	2 / 51 (3.92%)	0 / 14 (0.00%)	
occurrences (all)	2	0	
Refractoriness to platelet transfusion			

subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	0 / 14 (0.00%) 0	
Procedural pain subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	0 / 14 (0.00%) 0	
Infusion related reaction subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	0 / 14 (0.00%) 0	
Accidental overdose subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 14 (7.14%) 1	
Contusion subjects affected / exposed occurrences (all)	5 / 51 (9.80%) 6	2 / 14 (14.29%) 2	
Cardiac disorders Tachycardia subjects affected / exposed occurrences (all)	3 / 51 (5.88%) 4	1 / 14 (7.14%) 1	
Nervous system disorders Headache subjects affected / exposed occurrences (all)	10 / 51 (19.61%) 16	2 / 14 (14.29%) 6	
Syncope subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 14 (7.14%) 1	
Tremor subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	1 / 14 (7.14%) 1	
Dizziness subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	0 / 14 (0.00%) 0	
Blood and lymphatic system disorders Aplastic anaemia subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	0 / 14 (0.00%) 0	
Lymphadenopathy			

subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	0 / 14 (0.00%) 0	
Haemolysis subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 14 (7.14%) 1	
Febrile neutropenia subjects affected / exposed occurrences (all)	11 / 51 (21.57%) 17	3 / 14 (21.43%) 3	
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 14 (7.14%) 1	
Eye disorders Accommodation disorder subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 14 (7.14%) 1	
Choroidal effusion subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 14 (7.14%) 1	
Dry eye subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 3	0 / 14 (0.00%) 0	
Conjunctival haemorrhage subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 2	1 / 14 (7.14%) 2	
Eye pain subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 3	1 / 14 (7.14%) 2	
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	16 / 51 (31.37%) 21	3 / 14 (21.43%) 4	
Abdominal distension subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	0 / 14 (0.00%) 0	
Constipation			

subjects affected / exposed	6 / 51 (11.76%)	0 / 14 (0.00%)
occurrences (all)	6	0
Aphthous ulcer		
subjects affected / exposed	2 / 51 (3.92%)	1 / 14 (7.14%)
occurrences (all)	4	3
Chronic gastritis		
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)
occurrences (all)	1	1
Abdominal pain upper		
subjects affected / exposed	6 / 51 (11.76%)	1 / 14 (7.14%)
occurrences (all)	7	2
Periodontal disease		
subjects affected / exposed	2 / 51 (3.92%)	1 / 14 (7.14%)
occurrences (all)	2	1
Oral pain		
subjects affected / exposed	2 / 51 (3.92%)	1 / 14 (7.14%)
occurrences (all)	2	1
Oral blood blister		
subjects affected / exposed	2 / 51 (3.92%)	0 / 14 (0.00%)
occurrences (all)	2	0
Anal haemorrhage		
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)
occurrences (all)	1	1
Enterocolitis		
subjects affected / exposed	5 / 51 (9.80%)	2 / 14 (14.29%)
occurrences (all)	8	3
Gastritis		
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)
occurrences (all)	1	1
Gastrooesophageal reflux disease		
subjects affected / exposed	2 / 51 (3.92%)	0 / 14 (0.00%)
occurrences (all)	2	0
Diarrhoea		
subjects affected / exposed	10 / 51 (19.61%)	1 / 14 (7.14%)
occurrences (all)	15	4
Small intestinal obstruction		

subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)
occurrences (all)	1	1
Mucous stools		
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)
occurrences (all)	1	1
Nausea		
subjects affected / exposed	20 / 51 (39.22%)	3 / 14 (21.43%)
occurrences (all)	31	4
Odynophagia		
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)
occurrences (all)	3	3
Stomatitis		
subjects affected / exposed	8 / 51 (15.69%)	2 / 14 (14.29%)
occurrences (all)	10	4
Gingival hypertrophy		
subjects affected / exposed	7 / 51 (13.73%)	3 / 14 (21.43%)
occurrences (all)	8	3
Haematochezia		
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)
occurrences (all)	3	3
Gingival swelling		
subjects affected / exposed	3 / 51 (5.88%)	0 / 14 (0.00%)
occurrences (all)	3	0
Tongue ulceration		
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)
occurrences (all)	2	2
Mouth ulceration		
subjects affected / exposed	2 / 51 (3.92%)	1 / 14 (7.14%)
occurrences (all)	2	1
Vomiting		
subjects affected / exposed	21 / 51 (41.18%)	3 / 14 (21.43%)
occurrences (all)	38	7
Gingival pain		
subjects affected / exposed	2 / 51 (3.92%)	0 / 14 (0.00%)
occurrences (all)	2	0
Gingival bleeding		

subjects affected / exposed occurrences (all)	6 / 51 (11.76%) 10	1 / 14 (7.14%) 3	
Hepatobiliary disorders			
Hyperbilirubinaemia			
subjects affected / exposed	3 / 51 (5.88%)	1 / 14 (7.14%)	
occurrences (all)	4	2	
Jaundice			
subjects affected / exposed	2 / 51 (3.92%)	0 / 14 (0.00%)	
occurrences (all)	2	0	
Ocular icterus			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	3	3	
Skin and subcutaneous tissue disorders			
Erythema			
subjects affected / exposed	3 / 51 (5.88%)	2 / 14 (14.29%)	
occurrences (all)	3	2	
Petechiae			
subjects affected / exposed	5 / 51 (9.80%)	2 / 14 (14.29%)	
occurrences (all)	10	2	
Alopecia			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	1	1	
Ecchymosis			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	3	3	
Hirsutism			
subjects affected / exposed	5 / 51 (9.80%)	2 / 14 (14.29%)	
occurrences (all)	5	2	
Acne			
subjects affected / exposed	2 / 51 (3.92%)	1 / 14 (7.14%)	
occurrences (all)	2	1	
Pruritus			
subjects affected / exposed	5 / 51 (9.80%)	1 / 14 (7.14%)	
occurrences (all)	5	1	
Rash			



subjects affected / exposed	11 / 51 (21.57%)	1 / 14 (7.14%)	
occurrences (all)	12	1	
Rash maculo-papular			
subjects affected / exposed	4 / 51 (7.84%)	2 / 14 (14.29%)	
occurrences (all)	5	2	
Rash papular			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	1	1	
Skin hyperpigmentation			
subjects affected / exposed	4 / 51 (7.84%)	2 / 14 (14.29%)	
occurrences (all)	5	2	
Urticaria			
subjects affected / exposed	7 / 51 (13.73%)	1 / 14 (7.14%)	
occurrences (all)	9	3	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	5 / 51 (9.80%)	2 / 14 (14.29%)	
occurrences (all)	8	2	
Renal tubular acidosis			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	1	1	
Azotaemia			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	1	1	
Nephropathy toxic			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	1	1	
Paroxysmal nocturnal haemoglobinuria			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	1	1	
Renal failure			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	1	1	
Renal impairment			

subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 14 (7.14%) 1	
Endocrine disorders			
Adrenal insufficiency subjects affected / exposed occurrences (all)	3 / 51 (5.88%) 3	2 / 14 (14.29%) 2	
Cushingoid subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	1 / 14 (7.14%) 1	
Musculoskeletal and connective tissue disorders			
Pain in extremity subjects affected / exposed occurrences (all)	9 / 51 (17.65%) 11	4 / 14 (28.57%) 5	
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 3	1 / 14 (7.14%) 1	
Arthralgia subjects affected / exposed occurrences (all)	6 / 51 (11.76%) 9	2 / 14 (14.29%) 4	
Back pain subjects affected / exposed occurrences (all)	4 / 51 (7.84%) 5	2 / 14 (14.29%) 3	
Kyphosis subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 14 (7.14%) 1	
Tendon pain subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 14 (7.14%) 1	
Infections and infestations			
Rhinitis subjects affected / exposed occurrences (all)	4 / 51 (7.84%) 5	2 / 14 (14.29%) 2	
Respiratory tract infection viral subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 14 (7.14%) 1	
Pharyngitis			

subjects affected / exposed	3 / 51 (5.88%)	1 / 14 (7.14%)
occurrences (all)	3	1
Bacterial disease carrier		
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)
occurrences (all)	1	1
COVID-19		
subjects affected / exposed	2 / 51 (3.92%)	0 / 14 (0.00%)
occurrences (all)	2	0
Epididymitis		
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)
occurrences (all)	1	1
Escherichia bacteraemia		
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)
occurrences (all)	1	1
Fungal infection		
subjects affected / exposed	2 / 51 (3.92%)	1 / 14 (7.14%)
occurrences (all)	2	1
Gingivitis		
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)
occurrences (all)	1	1
Soft tissue infection		
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)
occurrences (all)	1	1
Nasopharyngitis		
subjects affected / exposed	2 / 51 (3.92%)	1 / 14 (7.14%)
occurrences (all)	2	1
Paronychia		
subjects affected / exposed	2 / 51 (3.92%)	0 / 14 (0.00%)
occurrences (all)	2	0
Molluscum contagiosum		
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)
occurrences (all)	1	1
Vascular device infection		
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)
occurrences (all)	1	1
Upper respiratory tract infection		

subjects affected / exposed	8 / 51 (15.69%)	1 / 14 (7.14%)	
occurrences (all)	11	2	
Tonsillitis			
subjects affected / exposed	5 / 51 (9.80%)	1 / 14 (7.14%)	
occurrences (all)	8	1	
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	4 / 51 (7.84%)	1 / 14 (7.14%)	
occurrences (all)	9	1	
Hypermagnesaemia			
subjects affected / exposed	1 / 51 (1.96%)	1 / 14 (7.14%)	
occurrences (all)	2	2	
Dehydration			
subjects affected / exposed	2 / 51 (3.92%)	0 / 14 (0.00%)	
occurrences (all)	2	0	
Fluid retention			
subjects affected / exposed	2 / 51 (3.92%)	0 / 14 (0.00%)	
occurrences (all)	2	0	
Hyperkalaemia			
subjects affected / exposed	3 / 51 (5.88%)	2 / 14 (14.29%)	
occurrences (all)	7	6	
Decreased appetite			
subjects affected / exposed	6 / 51 (11.76%)	1 / 14 (7.14%)	
occurrences (all)	6	1	
Hypervolaemia			
subjects affected / exposed	2 / 51 (3.92%)	0 / 14 (0.00%)	
occurrences (all)	2	0	
Hypokalaemia			
subjects affected / exposed	5 / 51 (9.80%)	1 / 14 (7.14%)	
occurrences (all)	6	1	
Hypomagnesaemia			
subjects affected / exposed	19 / 51 (37.25%)	4 / 14 (28.57%)	
occurrences (all)	30	9	
Hyponatraemia			
subjects affected / exposed	3 / 51 (5.88%)	2 / 14 (14.29%)	
occurrences (all)	5	4	

Vitamin D deficiency subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	0 / 14 (0.00%) 0	
Metabolic acidosis subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 3	2 / 14 (14.29%) 3	
Iron overload subjects affected / exposed occurrences (all)	6 / 51 (11.76%) 6	2 / 14 (14.29%) 2	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
25 April 2017	Provided further clarification of the study population in Cohort A. Provided dose modification guidelines for G3/4 AEs that are not liver related and are not AEs of special interest. Designated that selected hematology, biochemistry tests and Cyclosporine (CsA) levels could be performed by local lab to facilitate the management of the patients by the site.
16 August 2017	Modified the ECG monitoring plan to include ECG evaluations at Tmax (time of Cmax) after single dose and at steady-state with eltrombopag treatment. Updated to include additional ECG assessments.
21 December 2017	Introduced an optional consent form to allow for screening bone marrow aspirate and biopsy specimens to be sent to and analyzed by the central laboratory prior to enrollment.
05 October 2018	Provided guidance regarding the use of medications belonging to the azole class of antifungal agents. Provided guidance regarding patients already receiving CsA at the time of study entry. Provided guidance regarding appropriate follow up for patients who discontinue eltrombopag prior to completion of the 26-week Treatment Period. Clarified changes of tablets of eltrombopag used in this study, visit frequency during long-term follow up, and ECG monitoring plan.
20 August 2020	Aligned bone marrow aspirate collection with bone marrow biopsy at Week 12 and Week 78 in order to monitor clonal evolution in the early and late phases of study treatment. Clarified the secondary objectives. Clarified requirements prior to PK sampling. Modified the process of bone marrow karyotyping at screening and added additional probes to improve screening for chromosomal abnormalities. Clarified exclusion and inclusion criteria. Modified guidelines for eltrombopag dose adjustment. Clarified study treatment modifications in case of bone marrow fibrosis and cytogenetic abnormalities. Clarified which abnormalities will not be reported as AEs or SAEs. Modified clonal evolution reporting so that it is consistent across all ETB115 clinical trials. Modified treatment for eltrombopag and CsA to be permitted beyond Week 104.
16 April 2021	Aligned protocol sections 5.1 'Patient population' and 10.8 'Sample size calculation' to the Pediatric Investigation Plan (PIP) for SAA (EMA-000170-PIP03-13-M04). Modified objective for exploratory biomarker analysis. Added, as per Novartis guidance, risk mitigation procedures during the public health emergency declared by local or regional authorities.

20 April 2022	<p>Removed objective #14 exploratory biomarker analysis of assessing proteomics in urine samples as the sample size collected was inadequate to perform a rigorous data analysis and correlate with treatment effect.</p> <p>Clarified that eltrombopag re-initiation was allowed only during the Study Treatment phase until Week 26.</p> <p>Clarified that patients whose SAA progressed during the Follow-up and Long-term Follow-up Period were to be discontinued from the study and that they may receive any SAA therapy at the discretion of the treating physician outside this study.</p> <p>Clarified that any case of MDS or AML must be reported as an adverse event throughout the study, including the Follow-up Period or the Long-term Follow-up Period.</p> <p>Clarified that any cytogenetic abnormality detected was to be recorded in the Cytogenetics CRF, and if clinically significant, was to be reported as an adverse event.</p> <p>Clarified that SAA progression, as determined by the investigator, was to be reported as an adverse event throughout the study, including the Follow-up Period or the Long-term Follow-up Period.</p> <p>Clarified that patients who progressed to MDS/AML or receive HSCT will be discontinued from the study, and they will not be monitored during the Follow-up and Long-term Follow-up periods.</p>
---------------	---

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results.

Please use <https://www.novctrd.com> for complete trial results.

Notes: